Drugs News and Research

RSS

New breakthrough in progeria treatment

Pharmaceuticals that inhibit a specific enzyme may be useful in treating progeria, or accelerated aging in children. A new study performed at the Sahlgrenska Academy, University of Gothenburg, Sweden, indicates that the development of progeria in mice was inhibited upon reducing the production of this enzyme.

21 May 2013

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

20 May 2013

FDA designates Synageva's sebelipase alfa as Breakthrough Therapy for early onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.

20 May 2013

PRIUM creates Centers with Standards database for payer-clients

PRIUM, a medical intervention company that helps reduce the inappropriate use of prescription drugs on workers' compensation claims, wants to highlight good functional restoration clinics and chronic pain management clinics for its payer-clients.

20 May 2013

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.

20 May 2013

Peripherally inserted central catheters increase risk of dangerous blood clots

Touted for safety, ease and patient convenience, peripherally inserted central catheters have become many clinicians' go-to for IV delivery of antibiotics, nutrition, chemotherapy, and other medications.

20 May 2013

Targeting glucagon action: A new frontier for regulating diabetes

For the first time, scientists at the Toronto General Research Institute showed that targeting glucagon action in the brain may be a new frontier for regulating diabetes.

20 May 2013

Joint replacement surgery might be avoidable in the future, suggest scientists

Scientists at Johns Hopkins have turned their view of osteoarthritis inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, they now have evidence that the bone underneath the cartilage is also a key player and exacerbates the damage.

20 May 2013

Patients with treatment-resistant depression benefit from ketamine

Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the Icahn School of Medicine at Mount Sinai.

20 May 2013

Students receive Addiction Science Award at 2013 Intel International Science and Engineering Fair

An exploration of electronic "screen time" and sleep on mood, memory and learning was given the top Addiction Science Award at the 2013 Intel International Science and Engineering Fair - the world's largest science competition for high school students.

20 May 2013

First alcoholic drink during puberty increases risk of alcohol problems

Research shows that the earlier the age at which youth take their first alcoholic drink, the greater the risk of developing alcohol problems. Thus, age at first drink (AFD) is generally considered a powerful predictor of progression to alcohol-related harm.

18 May 2013

Study examines effects of smoking on cognitive functioning in AD individuals

Treatment for alcohol use disorders works best if the patient actively understands and incorporates the interventions provided in the clinic.

18 May 2013

Patient and physician prescribing information a powerful aide in drug marketing

The information allows drug makers to know which drugs a doctor is prescribing and how that compares to a colleague across town.

18 May 2013

Safety and efficacy evaluation methods for medical devices

Medical devices are any medical items that are neither a drug nor a biological product. In light of their different mechanisms, actions and regulatory requirements, medical device trail evaluations are much more complicated than drug trails due to their unique clinical practices.

18 May 2013

RUCDR Infinite Biologics creates new Genomics Technology Center

RUCDR Infinite Biologics, the world's largest university-based biorepository, has completed an $11.8 million renovation project to create a new Genomics Technology Center, comprising 12,500 square feet of laboratory, office, and storage space on the Busch Campus of Rutgers, The State University of New Jersey.

18 May 2013

EHRA EUROPACE 2013 to feature late breaking clinical trials

Attendees will have the opportunity to hear the results of cutting edge studies, and to learn about the new Guidelines which are likely to have a tremendous impact on the European health care system.

18 May 2013

Liberty University's challenge to the health law has a day in appellate court

Mathew Staver, the university's lawyer, told the 4th U.S. Circuit Court of Appeals panel that Liberty would face millions of dollars in penalties if it refuses to provide employee health insurance that violates its religious beliefs.

18 May 2013

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.

18 May 2013

Thioridazine works by weakening staphylococcal cell wall, new study reveals

In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as staphylococci (Staphylococcus aureus).

18 May 2013

UC Davis scientists detect novel molecular target for multiple sclerosis

Working with lab mice models of multiple sclerosis, UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved medications against MS.

17 May 2013